Integration into McKesson's Medical-Surgical Solutions marketplace serving a nationwide customer base
Toronto, Ontario--(Newsfile Corp. - June 30, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a leader in temperature-controlled medication solutions, is pleased to announce the expansion of its relationship with McKesson Medical-Surgical ("MMS"). The agreement, dated June 23, 2026, broadens the scope of collaboration to include full portfolio distribution across North America, enhanced B2B capabilities, and deeper integration into one of the largest healthcare marketplaces in the United States.
Highlights of the Partnership:
Full Portfolio Distribution: Inclusion of all TempraMed products, including VIVI Cap®, VIVI Cap Smart™, VIVI Epi™, and VIVI Med™, across the MMS sales and distribution network
Expanded B2B Reach: Access to a broad network of healthcare providers, including physician offices, ambulatory surgery centers, long-term care facilities, and home health organizations
Multi-Channel Commercialization: Distribution through Simply Medical, LLC (a MMS affiliate), B2B2C partners, and leading platforms such as Optum Now
Scalable Market Access: Integration into McKesson Medical-Surgical's marketplace, which aggregates approximately 270,000 SKUs and serves a nationwide customer base
McKesson Medical-Surgical is one of the largest and most established B2B healthcare distributors in North America, providing TempraMed with immediate access to a highly diversified and recurring customer base across non-acute care settings. This partnership marks a significant step in TempraMed's transition toward a more diversified revenue model, complementing its growing retail pharmacy footprint with scalable B2B distribution channels.
The inclusion of TempraMed's full product portfolio across McKesson Medical-Surgical's sales and distribution network is expected to enhance product visibility, streamline procurement for healthcare providers, and accelerate adoption of the Company's proprietary thermal protection solutions across multiple care settings.
Ron Nagar, CEO of TempraMed, commented: "Our relationship with McKesson Medical-Surgical represents an important step in advancing our North American commercial strategy. Through this distribution arrangement, TempraMed expects to improve access to its temperature management solutions across a broader range of non-acute care providers and healthcare channels.
By making our full portfolio available through McKesson Medical-Surgical's distribution network, we aim to simplify product availability for healthcare professionals and patients managing temperature-sensitive medications. We believe this expanded reach will support broader market awareness and facilitate future commercial growth.